A Randomized, Open-label, Multiple-centre Study of Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced NSCLC With EGFR Mutation Positive
Phase of Trial: Phase IV
Latest Information Update: 29 Nov 2017
At a glance
- Drugs Gefitinib (Primary) ; Carboplatin; Gemcitabine
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Nov 2017 Status changed from recruiting to discontinued.
- 10 Jun 2017 Biomarkers information updated
- 20 Jan 2015 Status changed from not yet recruiting to recruiting, according to ClinicalTrials.gov record.